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Patients with chronic kidney disease (CKD) are well known to have a higher prevalence of cardiovascular disease from
epidemiological studies. Recently, CKD has also been shown to be related to neurological disorders, not only ischemic brain
injury but also cognitive impairment.This cerebrorenal connection is considered to involvesmall vessel disease in both the kidney
and brain, based on their hemodynamic similarities. Clinical studies suggest that markers for CKD such as estimated glomerular
ﬁltration rate (eGFR), proteinuria, and albuminuria may be helpful to predict brain small vessel disease, white matter lesions
(WMLs), silent brain ischemia (SBI), and microhemorrhages. Recently, changes in the vascular system of the brain have been
shown to contribute to the onset and progression of cognitive impairment, not only vascular dementia but also Alzheimer’s
disease. Patients with CKD are also reported to have higher risk of impaired cognitive function in the future compared with
non-CKD subjects. These results indicate that CKD markers may be helpful to predict the future risk of neuronal disease.
1.Introduction
Recently, the relation between chronic kidney disease (CKD)
and neurological disorders, not only cerebrovascular disease
such as ischemic brain injury but also cognitive impair-
ment such as Alzheimer’s disease, has been highlighted.
This cerebrorenal interaction is considered to be based on
small vessel disease. Cerebral and glomerular small vessel
disease might have a common soil of pathogenesis, as
these organs are closely connected with each other through
anatomic and vasoregulatory similarities. Because small
vessel disease is a systemic disorder, information about small
vessel disease in one organ may provide information on
damage in another organ. For the kidney, damage markers
are albuminuria/proteinuria and a reduction in estimated
glomerular ﬁltration rate (eGFR), which is also a marker
of CKD. On the other hand, damage markers in the brain
could be magnetic resonance imaging- (MRI-) documented
small vessel alterations. Recently, clinical investigations have
suggested a relation between these damage markers in the
kidney and the brain. Here, we review the cerebrorenal
interactions mainly from a clinical view.
2.ClinicalRelationbetweenCKDand
CerebrovascularDisease
2.1. Stroke. Recently, the relation between CKD and the
onset of stroke has been highlighted. The Northern Man-
hattan Study (NOMAS), which followed 3298 stroke-free
subjects for vascular outcomes with a mean follow-up time
of 6.5 years, showed that CKD, which was estimated using
serum creatinine and the Cockcroft-Gault formula, between
15 and 59mL/min is a strong risk factor for stroke (hazard
ratio (HR) = 2.65) [1]. In contrast, Bos et al. demonstrated
that decreased eGFR (<60mL/min/1.73m2) is a strong risk
factor for hemorrhagic but not ischemic stroke (HR = 4.10
forhemorrhagic strokeversus0.87forischemicstroke)inthe
Rotterdam Study [2]. The authors considered two hypothe-
ses for this relation. The ﬁrst, decreased GFR indicates small
vessel disease not only in the kidney but also in the brain.
Small vessel disease seems to be the main pathophysiological
mechanism in hemorrhage rather than brain infarction;
therefore, the authors suggested that GFR may be a marker
of cerebral small vessel disease, especially hemorrhage. The
second, the authors considered platelet dysfunction to be2 Cardiology Research and Practice
an inducible factor by CKD. Severe CKD patients show
prolonged bleeding time and mucosal oozing [3], indicating
that platelet dysfunction may be involved in the relation
between eGFR and hemorrhagic stroke. In the relation
between microalbuminuria and incident stroke, prospective
cohort studies using meta-analysis with 12 prospective
cohort studies including 48,596 individuals with more than
1200 stroke events have been very recently published [4].
The presence of microalbuminuria was greatly associated
with stroke onset even after adjustment for cardiovascular
risk factors (overall HR 1.92), indicating that albuminuria
contributetobeastrongpredictorfortheincidenceofstroke.
Recently,asymptomatic cerebralsmall vesseldiseasehasbeen
investigated as a predictor of the risk of future stroke. Oksala
etal.demonstratedthatcerebralsmall vesseldisease isclosely
associated withkidneyfunctioninpatientswithacutestroke.
Patients with cerebral small vessel disease and impaired
kidney function (eGFR < 60mL/min/1.73m2) exhibit poor
poststroke survival [5]. These results indicate that Repre-
sentative cerebral small vessel diseases include white matter
lesions (WMLs), silent brain infarction (SBI), and microhe-
morrhages aswellaslacunarinfarcts andsubcorticalatrophy.
2.2. White Matter Lesions. WMLs are detected as hyperin-
tense areas on T2-weighted MRI in areas that are bilaterally
and symmetrically sited in the hemispheric white matter.
The prevalence of WMLs is signiﬁcantly related to the
risk of stroke, cognitive decline, and dementia [6–8]. The
NOMAS demonstrated that white matter hyperintensity
volume is associated with moderate-to-severe CKD, which
was estimated using serum creatinine and the Cockcroft-
Gault formula, between 15 and 59mL/min [9]. Wada et al.
demonstrated that subjects with lower eGFR (less than
60mL/min/1.73m2) tended to have more lacunar infarcts
and higher grade of WMLs; moreover, mean grade of WMLs
and the mean number of lacunar infarcts in subjects with
albuminuria were greater than those in subjects without
albuminuria [10]. Furthermore, they also reported that
urinary albumin level was associated with cerebral small
vessel disease, independently of traditional cerebrovascular
risk factors, in community-based elderly [11]. Similarly,
Ikrametal.investigatedtherelationbetweenkidneyfunction
evaluated by eGFR and cerebral small vessel disease via
MRI analysis. They clearly showed that decreased eGFR was
related to subclinical markers of cerebral small vessel disease
such asdeepwhite mattervolumeand WNLsindependentof
cardiovascular risk factors such as age, sex, blood pressure,
and diabetes [12]. Interestingly, they also demonstrated
that persons with lower eGFR had a smaller brain volume,
indicating that CKD may relate to brain atrophy.
2.3.SilentBrain Infarction. Ontheotherhand, SBIisdeﬁned
as a cerebral infarction detected by brain imaging without
clinicalsymptoms. Kobayashi etal. also reported that there is
an independentassociation between SBIand eGFR [13]. The
prevalenceofSBIandthenumberofSBIsincreasedmarkedly
as eGFR decreased. The presence of SBI is reported to
predictclinicalovertstroke[14,15]orcognitiveimpairment.
Therefore, patients with CKD should be assessed for SBI by
MRI during the follow-up period. In contrast, Uzu et al.
followed 608 patients with type 2 diabetes for 7.5 years and
very recently reported that SBI may predict the progression
of kidney disease in these patients [16]. The risk of end-
stage renal disease (ESRD) or death was signiﬁcantly higher
in patients with SBI than in those without (HR 2.44). The
estimated eGFR declined more in patients with SBI than in
those without; however, the presence of SBI did not increase
the risk of progression of albuminuria.
2.4. Microhemorrhages. Microhemorrhages are discrete or
isolated punctate hypointense lesions smaller than 5mm on
T2∗-weightedMRI.Theyareconsideredtobeclinicallysilent
but are strongly associated with advanced small vessel or
microvascular ischemic disease [17, 18]a n dt ob eam a r k e r
for increased risk of future intracranial hemorrhage [19, 20].
Interestingly, Cho et al. showed that lower eGFR is associ-
ated with the presence of cerebral microhemorrhages [21].
Moreover, proteinuria is also strongly associated with both
the frequency and number of cerebral microhemorrhages in
patients with recent cerebral ischemia [22]. Therefore, CKD
may increase therisk of hemorrhagic microangiopathy in the
brain.
2.5. Hypertensive Nephroangiosclerosis. Hypertensive neph-
roangiosclerosis was observed in 25% of patients with ESRD
in the United States [23]. Because nephroangiosclerosis is
alsomostlyclinicallysilent,itsprevalenceinstrokepatientsis
not well known. A recent autopsy data bank clearly demon-
strated that nephroangiosclerosis is commoninpatientswith
fatal stroke. Indeed, nephroangiosclerosis is independently
associated with the prevalence or history of hypertension in
stroke patients (39.8% of patients with stroke versus 9.0% of
patients with other neurologic diseases) [24]. These results
suggest that senile kidney change is also commonly observed
in patients with cerebrovascular disease and a true relation
betweenkidneydysfunctionandcerebralsmall vesseldisease;
however, the factors connecting kidney dysfunction and
cerebrovascular disease remain under discussion.
3.ClinicalRelationbetweenCKDand
CognitiveImpairment
Dementia and cognitive decline impair the quality of
life and are associated with a profound disease burden,
morbidity, and mortality, not only in patients but also
in caregivers. Although an earlier approach to prevent
cognitive dysfunction has been expected, there are few
markers for evaluating the future risk of cognitive decline
in subjects. Recently, impaired kidney function was reported
to be associated with dementia and cognitive impairment.
The REasons for Geographic and Racial Diﬀerences in
Stroke (REGARDS) Study with 23,405 participants showed
that reduced kidney function is associated with a higher
prevalence of cognitive impairment [25]. In patients with
CKD, each 10mL/min/1.73m2 decrease in eGFR below
60mL/min/1.73m2 was associated with an 11% increasedCardiology Research and Practice 3
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Figure 1: Schematic representation of cerebrorenal connection. RAS: renin-angiotensin system, CKD: chronic kidney disease, eGFR:
estimated glomerular ﬁltration rate, WMLs:white matter lesions,and SBI: silent brain infarction.
prevalence of cognitive impairment (HR = 1.11). Yaﬀee t
al. conducted a chronic renal insuﬃciency cohort cognitive
study in 825 adults aged 55 and older with CKD [26]. Par-
ticipants with advanced CKD (eGFR < 30mL/min/1.73m2)
were more likely to have clinically signiﬁcant impairment
of global cognition than those with mild-to-moderate
CKD (eGFR 45–59mL/min/1.73m2)( H R= 2.0). Moreover,
Buchman et al. reported a prospective, observational cohort
study in 886 elderly without dementia [27]. Impaired kidney
function (eGFR < 60mL/min/1.73m2) at baseline was asso-
ciated with a more rapidly decline in cognitive, especially in
semantic memory, episodic memory, and working memory.
In contrast, Jassal et al. very recently demonstrated that
baseline albuminuria, but not eGFR, was associated with
reduced cognitive function only in men [28]. They indicated
that albuminuria was a simple predictor of future cognitive
decline. Although there is sex diﬀerence in the relation
between albuminuria and cognitive impairment, kidney
function may provide an important window on future cog-
nitive impairment. Recently, changes in the vascular system
in the brain have been shown to contribute to the onset
and progression of dementia [29]. The so-called “central
nervous system (CNS)neurovascular unit” is linked to many
common human CNS pathological conditions including
dementia. Although multiple mechanisms are involved in
cognitive impairment and dementia associated with CKD,
small vessel disease in thekidney and brain is also considered
to have a key role in this connection.
4.Hemodynamic Similarities of Vascular Beds
betweenKidneyand Brain
Unlike most organs, both the kidney and brain are low
resistance end-organs thatare exposed tohigh-volumeblood
ﬂow throughout the cardiac cycle. These hemodynamic
similarities are observed in the vascular beds in the kidney
and the brain [30]; therefore, small vessel disease in the
kidneymaylet us knowofthepresence ofsmall vessel disease
in the brain. Ito et al. proposed the very interesting “strain
vessel hypothesis” as a possible mechanism for cerebro-
cardio-renal connections [31]. Based on the similarity of
the juxtamedullary aﬀerent arterioles in the kidney to the
perforating arteries in the brain, they are thought to be
evolutionally developed to maintain the perfusion of vital
tissues such as nephrons and the brainstem directly from
large arteries to deliver blood to the tissue. These “strain
vessels” are exposed to very high pressure and maintain
a high vascular tone. Vascular damage induced by high
arterial blood pressure and diabetes mellitus occurs in these
similar strain vessels; therefore, microalbuminuria may be an
indicator of vascular damage not only in the kidney but also
in the brain. One of the common molecular components of
small-vessel physiology that may also mediate microvascular
dysfunction or injury is nitric oxide. Many papers have
reported that nitric oxide deﬁciency could occur in renal
disease, and this subject was been well reviewed by Baylis
[32]. Nitric oxide regulates the microcirculation and the
blood brain barrier [33], both of which are implicated in
the developmentof WMLs and other manifestations of small
vessel disease in the brain. Moreover, patients with impaired
cognitive function show increased levels of endogenous
inhibitors of nitric oxide synthesis and decreased nitric oxide
metabolites [34]. Therefore, decreased nitric oxide may be
one of the key factors in the cerebrorenal connection.
5.PreventionandFuturePerspectives
These reports above strongly suggest that a brain and kidney
connection exists and that systematic treatment targeting
small vessel disease is therapeutically eﬀective on not only
theapparentdamagedorganbutalsoonthesilentlydamaged
organs (Figure 1). According to their unique shared suscep-
tibility to vascular injury from central aortic pressure as4 Cardiology Research and Practice
a strain vessel, a logical preventive approach to cerebrorenal-
related dysfunction is to achieve a reduction of central pulse
pressure. A reduction of the central pulse pressure involves
a reduction of the wave reﬂection by dilation of conduit
arteries, since drugs do not directly aﬀect the aorta and
large arteries. Therefore, antihypertensive drugs should be
selected to reduce the central pulse pressure, such as renin-
angiotensin system (RAS) blockers and calcium-channel
antagonists (CCB). For the kidney, there is good evidence
from large clinical studies that blockade of RAS is highly
eﬀective to prevent renal damage compared with other
antihypertensive drugs. In the brain, recent large clinical
trials indicate that RAS blockade with angiotensin receptor
blockers (ARBs) is eﬀective to prevent a ﬁrst or recurrent
stroke beyond their blood pressure-lowering eﬀect [35–37].
Moreover, a very recent paper clearly demonstrated that
patientstreated withARBshave lessseveredeﬁcitafterstroke
[38]. These results suggest that treatment with ARBs may be
eﬀectivenot onlytoreduce bloodpressure butalso toprotect
boththekidneyandbrain via preventingsmall vessel disease.
However, the Blood Pressure Lowering Treatment Trialists’
Collaboration (BPLTTC) demonstrates that all of the blood
pressure-lowering regimens have broadly similar protection
against stroke [39]. Moreover, there are not any large clinical
studies that demonstrate the eﬀect of ARBs on dementia or
cognitive impairment. Therefore, there is few evidence of the
preventiveeﬀectofRASblockadeinthebraincomparedwith
that in the kidney. On the other hand, CCBs are proved to
have preventive eﬀect on dementia in the Systolic Hyperten-
sion in Europe (Syst-Eur) study [40]. CCB, nitrendipine was
found to be eﬀective to reduce the incidence of dementia.
This is the only large clinical study that shows the eﬀect
of anti-hypertensive drug on dementia. Although several
CCBs are reported to have renoprotective eﬀects, generally
CCBs do not have a remarkable eﬀect on CKD prevention
compared with RAS blockade due to the preferentially dilate
aﬀerent arteriole. Therefore, preventive eﬀect of CCBs on
cerebrorenal connection is also still under investigation.
Furthermore,althoughhypertensionmaybeinvolvedineach
pathological change in brain and kidney, it can be result
of high blood pressure “in parallel,” indicating that direct
evidence of common mechanistic factors in hypertension-
induced cerebrorenal damage is still under investigation.
6.Conclusion
A cerebro-renal connection exists clinically. CKD markers
may be helpful to evaluate the future risk of neuronal
disease (Figure 1). Further investigation of the brain-kidney
connectionmaycontributetopreventionofimpaired quality
of life from multiple organ dysfunction due to small vessel
disease. Furthermore, protection of the damaged organ will
shift to protection of multiple hidden damaged organs,
focusing on systemic small vessel disease.
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